PT1765289E - Composições e processos para estabilizar formulações de adjuvantes à base de lípidos por meio de glicolípidos - Google Patents
Composições e processos para estabilizar formulações de adjuvantes à base de lípidos por meio de glicolípidos Download PDFInfo
- Publication number
- PT1765289E PT1765289E PT05756461T PT05756461T PT1765289E PT 1765289 E PT1765289 E PT 1765289E PT 05756461 T PT05756461 T PT 05756461T PT 05756461 T PT05756461 T PT 05756461T PT 1765289 E PT1765289 E PT 1765289E
- Authority
- PT
- Portugal
- Prior art keywords
- glycolipids
- compositions
- methods
- lipid based
- based adjuvant
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229930186217 Glycolipid Natural products 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 150000002632 lipids Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
- 239000002502 liposome Substances 0.000 abstract 4
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 239000012467 final product Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200401070 | 2004-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1765289E true PT1765289E (pt) | 2008-12-05 |
Family
ID=34982425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05756461T PT1765289E (pt) | 2004-07-07 | 2005-07-05 | Composições e processos para estabilizar formulações de adjuvantes à base de lípidos por meio de glicolípidos |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1765289B1 (pt) |
| JP (1) | JP4987704B2 (pt) |
| KR (1) | KR101275837B1 (pt) |
| CN (1) | CN1980638B (pt) |
| AT (1) | ATE406874T1 (pt) |
| AU (1) | AU2005259685B2 (pt) |
| BR (1) | BRPI0512757B8 (pt) |
| CA (1) | CA2572985C (pt) |
| DE (1) | DE602005009535D1 (pt) |
| DK (1) | DK1765289T3 (pt) |
| ES (1) | ES2315880T3 (pt) |
| PL (1) | PL1765289T3 (pt) |
| PT (1) | PT1765289E (pt) |
| SI (1) | SI1765289T1 (pt) |
| WO (1) | WO2006002642A2 (pt) |
| ZA (1) | ZA200701043B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008000261A2 (en) * | 2006-06-28 | 2008-01-03 | Statens Serum Institut | Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
| ES2611924T3 (es) | 2006-10-03 | 2017-05-11 | Arbutus Biopharma Corporation | Formulaciones que contienen lípidos |
| PL2167124T3 (pl) | 2007-06-29 | 2012-12-31 | Statens Seruminstitut | Zastosowanie monomikoliloglicerolu (MMG) jako adiuwantu |
| US20110280930A1 (en) | 2008-05-02 | 2011-11-17 | Facundo Batista | Products and methods for stimulating an immune response |
| PT2385980T (pt) * | 2009-01-08 | 2018-06-26 | Albert Einstein College Medicine Inc | Vacinas bacterianas com glicolípidos do tipo ceramida associados à parede celular e utilização dos mesmos |
| CN102482666B (zh) * | 2009-07-06 | 2017-02-08 | 变异生物技术公司 | 制备囊泡的方法和由其产生的制剂 |
| JP5933538B2 (ja) * | 2010-07-02 | 2016-06-08 | インターベット インターナショナル ベー． フェー． | エーリキア・カニスに対するワクチンおよび関連する方法 |
| US20140112979A1 (en) | 2011-07-04 | 2014-04-24 | Statens Serum Institut | Methods for producing liposomes |
| JP6182457B2 (ja) * | 2011-12-12 | 2017-08-16 | 協和発酵キリン株式会社 | カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子 |
| WO2013089152A1 (ja) * | 2011-12-12 | 2013-06-20 | 協和発酵キリン株式会社 | カチオン性脂質の組み合わせを含有する脂質ナノ粒子 |
| JP2016175841A (ja) * | 2013-08-02 | 2016-10-06 | 三郎 斎藤 | リポソームと、細胞障害性ｔ細胞活性を誘導するワクチン組成物 |
| BR112016005948A2 (pt) * | 2013-09-19 | 2017-09-26 | Zoetis Services Llc | adjuvantes com base em óleo |
| CN106535933B (zh) * | 2014-08-04 | 2021-09-17 | 日东电工株式会社 | 包含核受体配体的免疫诱导促进用组合物以及疫苗药物组合物 |
| BR112018001318B1 (pt) * | 2015-07-20 | 2023-11-14 | Zoetis Services Llc | Lipossoma livre de saponina, formulação adjuvante, composição de vacina, uso terapêutico de um componente antigênico e da formulação adjuvante e método para preparar o referido lipossoma |
| US12064480B2 (en) | 2018-04-13 | 2024-08-20 | Glaxosmithkline Biologicals Sa | Immunigenic alpha-branched trehalose-diesters |
| CN114657147B (zh) * | 2022-01-27 | 2023-12-01 | 安徽智飞龙科马生物制药有限公司 | 一种生物材料的保护剂及其应用 |
| CN115068602B (zh) * | 2022-08-22 | 2022-11-01 | 北京华诺泰生物医药科技有限公司 | 一种表面改性氧化铝的复合疫苗佐剂、制备方法及应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5108934A (en) * | 1983-11-30 | 1992-04-28 | Kabushiki Kaisha Toshiba | Quantitative immunoassay utilizing liposomes |
| JP2714972B2 (ja) * | 1988-02-02 | 1998-02-16 | 千葉製粉株式会社 | リン脂質集合体用修飾剤、リン脂質小胞体用凝集防止剤、リン脂質小胞体用融合防止剤およびリン脂質膜用表面固定化剤 |
| JPH03249561A (ja) * | 1990-02-28 | 1991-11-07 | Toshiba Corp | 免疫分析試薬 |
| JPH0482824A (ja) * | 1990-07-23 | 1992-03-16 | Nippon Oil & Fats Co Ltd | リポソーム及び水中油型エマルション |
| JPH0616688A (ja) * | 1992-06-30 | 1994-01-25 | Nippon Oil & Fats Co Ltd | 脂肪酸糖エステル |
| JP3884488B2 (ja) * | 1993-03-10 | 2007-02-21 | 千葉製粉株式会社 | オリゴ糖脂質 |
| JP3329554B2 (ja) * | 1993-03-10 | 2002-09-30 | 千葉製粉株式会社 | 乾燥小胞体 |
| US5885613A (en) * | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| JPH0925287A (ja) * | 1995-07-13 | 1997-01-28 | Eisai Co Ltd | 合成脂質 |
| JPH09110722A (ja) * | 1995-10-20 | 1997-04-28 | Toray Ind Inc | 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法 |
| US6183774B1 (en) * | 1996-01-31 | 2001-02-06 | Collaborative Laboratories, Inc. | Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts |
| US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| GB9808268D0 (en) * | 1998-04-17 | 1998-06-17 | Imp College Innovations Ltd | Compound |
| GB0007150D0 (en) * | 2000-03-24 | 2000-05-17 | Lamellar Therapeutics Limited | Immunotherapeutic methods and compositions |
| AU2002311616B2 (en) * | 2001-06-25 | 2007-11-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method for preparation of vesicles loaded with biological material and different uses thereof |
-
2005
- 2005-07-05 ES ES05756461T patent/ES2315880T3/es active Active
- 2005-07-05 JP JP2007519615A patent/JP4987704B2/ja active Active
- 2005-07-05 DE DE602005009535T patent/DE602005009535D1/de active Active
- 2005-07-05 WO PCT/DK2005/000467 patent/WO2006002642A2/en active Application Filing
- 2005-07-05 AU AU2005259685A patent/AU2005259685B2/en active Active
- 2005-07-05 SI SI200530467T patent/SI1765289T1/sl unknown
- 2005-07-05 PL PL05756461T patent/PL1765289T3/pl unknown
- 2005-07-05 EP EP05756461A patent/EP1765289B1/en active Active
- 2005-07-05 BR BRPI0512757A patent/BRPI0512757B8/pt active IP Right Grant
- 2005-07-05 CA CA2572985A patent/CA2572985C/en active Active
- 2005-07-05 AT AT05756461T patent/ATE406874T1/de active
- 2005-07-05 PT PT05756461T patent/PT1765289E/pt unknown
- 2005-07-05 DK DK05756461T patent/DK1765289T3/da active
- 2005-07-05 CN CN200580022926XA patent/CN1980638B/zh active Active
- 2005-07-05 KR KR1020077002648A patent/KR101275837B1/ko active IP Right Review Request
-
2007
- 2007-02-05 ZA ZA200701043A patent/ZA200701043B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006002642A2 (en) | 2006-01-12 |
| ZA200701043B (en) | 2007-12-27 |
| KR101275837B1 (ko) | 2013-06-18 |
| KR20070051847A (ko) | 2007-05-18 |
| ATE406874T1 (de) | 2008-09-15 |
| AU2005259685A1 (en) | 2006-01-12 |
| CN1980638A (zh) | 2007-06-13 |
| JP4987704B2 (ja) | 2012-07-25 |
| CN1980638B (zh) | 2011-10-12 |
| CA2572985A1 (en) | 2006-01-12 |
| BRPI0512757A (pt) | 2008-04-08 |
| PL1765289T3 (pl) | 2009-02-27 |
| AU2005259685B2 (en) | 2010-04-08 |
| BRPI0512757B8 (pt) | 2021-05-25 |
| EP1765289B1 (en) | 2008-09-03 |
| SI1765289T1 (sl) | 2009-02-28 |
| CA2572985C (en) | 2014-04-22 |
| EP1765289A2 (en) | 2007-03-28 |
| DK1765289T3 (da) | 2008-12-15 |
| JP2008505131A (ja) | 2008-02-21 |
| ES2315880T3 (es) | 2009-04-01 |
| WO2006002642A3 (en) | 2006-05-18 |
| BRPI0512757B1 (pt) | 2021-04-06 |
| DE602005009535D1 (de) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200701043B (en) | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids | |
| Levast et al. | Vaccine potentiation by combination adjuvants | |
| MX2010001054A (es) | Composiciones adyuvantes antigenicas y metodos. | |
| WO2009111088A3 (en) | Antitumor immunization by liposomal delivery of vaccine to the spleen | |
| RU2013114392A (ru) | Маленькие липосомы для доставки кодирующей иммуноген рнк | |
| WO2000057917A3 (en) | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines | |
| WO2015130584A3 (en) | Lipid nanoparticle vaccine adjuvants and antigen delivery systems | |
| CA2448208A1 (en) | Influenza vaccine composition | |
| WO2005016239A3 (en) | Molecules enhancing dermal delivery of influenza vaccines | |
| AU2002254901A1 (en) | Influenza vaccine formulations for intradermal delivery | |
| SG170127A1 (en) | Vaccine compositions comprising a saponin adjuvant | |
| MY126588A (en) | Intranasal influenza virus vaccine | |
| WO2002028422A3 (en) | Split enveloped virus preparation for intranasal delivery | |
| HUP0101619A2 (hu) | Adjuvánskészítmények | |
| WO2000062800A3 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide | |
| MX2009008928A (es) | Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas. | |
| WO2011027257A3 (en) | Pcsk9 vaccine | |
| EE05633B1 (et) | Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine | |
| GB2386072A (en) | Novel vaccine | |
| ZA202101465B (en) | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery | |
| TW200510538A (en) | Functionally reconstituted viral membranes containing adjuvant | |
| ATE419873T1 (de) | Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs | |
| WO2008093772A1 (ja) | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 | |
| AU6721801A (en) | The use of plant oil-bodies in vaccine delivery systems | |
| AU2003255275A1 (en) | Improved anthrax vaccines and delivery methods |